Published 21 days ago • loading... • Updated 21 days ago

Agenus Receives Investment From Zynext Ventures

Summary by FinSMEs

Agenus, a Lexington, MA-based immuno-oncology company developing new therapeutics for high-unmet need cancers, received an investment from Zynext Ventures. The amount of the deal was not disclosed. Led by CEO Dr. Garo Armen, Agenus develops a lead program comprising Botensilimab (BOT) and Balstilimab (BAL), which is a new immunotherapy platform designed to strengthen and sustain the […] The post Agenus Receives Investment from Zynext Ventures ap…

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All

Left

Center

Right

FinSMEs

Agenus Receives Investment from Zynext Ventures

21 days ago

Read Full Article

endpoints.news

Agenus quickly exits CDMO business by selling assets to Zydus for $75M upfront

Agenus is divesting its biologics CDMO business, which it launched only six months ago, to Indian drugmaker Zydus Lifesciences for $75 million upfront, an Agenus spokesperson told Endpoints News ...

21 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right